Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Endometrial Adenocarcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 10fludarabine 7trametinib 6Specimen Handling 6Mycophenolic Acid 6Whole-Body Irradiation 5Sirolimus 5Nivolumab 5Biopsy 5fludarabine phosphate 4Magnetic Resonance Spectroscopy 4dabrafenib 3Prednisone 3Melphalan 3Ipilimumab 3GSK2636771 3Filgrastim 3Electrocardiography 3Crizotinib 3CTLA-4 Antigen 3Busulfan 3palbociclib 2osimertinib 2keyhole-limpet hemocyanin 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Mesna 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Neoplasms × GSK2141795 × Clear all
NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled 16 charts
DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡